» Articles » PMID: 15750180

Nuclear Poly(ADP-ribose) Polymerase-1 Rapidly Triggers Mitochondrial Dysfunction

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2005 Mar 8
PMID 15750180
Citations 67
Authors
Affiliations
Soon will be listed here.
Abstract

To obtain further information on time course and mechanisms of cell death after poly(ADP-ribose) polymerase-1 (PARP-1) hyperactivation, we used HeLa cells exposed for 1 h to the DNA alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine. This treatment activated PARP-1 and caused a rapid drop of cellular NAD(H) and ATP contents, culminating 8-12 h later in cell death. PARP-1 antagonists fully prevented nucleotide depletion and death. Interestingly, in the early 60 min after challenge with N-methyl-N'-nitro-N-nitrosoguanidine, mitochondrial membrane potential and superoxide production significantly increased, whereas cellular ADP contents decreased. Again, these events were prevented by PARP-1 inhibitors, suggesting that PARP-1 hyperactivity leads to mitochondrial state 4 respiration. Mitochondrial membrane potential collapsed at later time points (3 h), when mitochondria released apoptosis-inducing factor and cytochrome c. Using immunocytochemistry and targeted luciferase transfection, we found that, despite an exclusive localization of PARP-1 and poly(ADP-ribose) in the nucleus, ATP levels first decreased in mitochondria and then in the cytoplasm of cells undergoing PARP-1 activation. PARP-1 inhibitors rescued ATP (but not NAD(H) levels) in cells undergoing hyper-poly(ADP-ribosyl)ation. Glycolysis played a central role in the energy recovery, whereas mitochondria consumed ATP in the early recovery phase and produced ATP in the late phase after PARP-1 inhibition, further indicating that nuclear poly(ADP-ribosyl)ation rapidly modulates mitochondrial functioning. Together, our data provide evidence for rapid nucleus-mitochondria cross-talk during hyper-poly(ADP-ribosyl)ation-dependent cell death.

Citing Articles

Melatonin derivative 6a as a PARP-1 inhibitor for the treatment of Parkinson's disease.

Ma Q, Han R, Wu Z, Zhou J, Chen M, Zhang X Front Pharmacol. 2024; 15:1363212.

PMID: 38476326 PMC: 10927953. DOI: 10.3389/fphar.2024.1363212.


The Role of Poly(ADP-ribose) Polymerase 1 in Nuclear and Mitochondrial Base Excision Repair.

Herrmann G, Yin Y Biomolecules. 2023; 13(8).

PMID: 37627260 PMC: 10452840. DOI: 10.3390/biom13081195.


FBXW7 alleviates hyperglycemia-induced endothelial oxidative stress injury via ROS and PARP inhibition.

Li S, Deng J, Sun D, Chen S, Yao X, Wang N Redox Biol. 2022; 58:102530.

PMID: 36427396 PMC: 9692029. DOI: 10.1016/j.redox.2022.102530.


Combined analysis of whole-exome sequencing and RNA sequencing in type 2 diabetes mellitus patients with thirst and fatigue.

Lv B, Yang X, An T, Wu Y, He Z, Li B Diabetol Metab Syndr. 2022; 14(1):111.

PMID: 35941691 PMC: 9358875. DOI: 10.1186/s13098-022-00884-z.


Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy.

Li K, You J, Wu Q, Meng W, He Q, Yang B Acta Pharm Sin B. 2021; 11(9):2738-2748.

PMID: 34589394 PMC: 8463275. DOI: 10.1016/j.apsb.2021.01.002.